Our Team

Shengfang Jin, Board Director, President and CSO

Shengfang brings to ENSEM over 25 years of biotech and pharma experience in Oncology and Rare Genetic Disease therapeutics development. As President and CSO, she is driving ENSEM’s strategic initiatives, technology platforms, science, and R&D. Previously, Shengfang was Vice President of Discovery Biology at Editas Medicine (EDIT), a clinical-stage gene editing company. Her teams pioneered the discovery of transformative, durable, CRISPR gene and cell therapy medicines focusing on ophthalmology, neural, and oncology diseases. Prior to Editas, Shengfang was Senior Director Biology at Agios Pharmaceuticals, leading the Small Molecule Cancer Metabolism and Rare Genetic Disease Portfolios, culminating in the approved & first-in-class products (IDHIFA®, TIBSOVO®, PYRUKYND®) and other clinical stage programs. Shengfang held roles of increasing responsibilities in Cambridge drug discovery companies, as Director, Molecular and Cellular Pharmacology at Gene Logic, Senior Scientist and Oncology Project Team Leader at Millennium Pharmaceuticals (Takeda), and Staff Scientist in Gene Therapy & Biotherapeutics at TKT (Shire). Shengfang is a passionate & enthusiastic motivator, empowering team members to lead and shine.

Shengfang is coauthor/coinventor of over 80 peer-reviewed publications and issued patents. She holds a PhD in Molecular Biology and Microbiology from Tufts Medical School (Boston) and obtained postdoctoral training in Oncology and Tumor Immunology at Harvard Medical School (Boston) as an NIH Fellow.